Patients Coming Off Anti-Obesity Medications Gain Back Pounds Far More Rapidly Compared to Dieters

A recent study suggests that individuals who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end conventional diet and exercise plans.

Published data in a leading medical journal points out that while obese people can lose about a fifth of their total mass while on the medication, the mass comes back at an average rate of nearly a kilo each month once they quit.

"Users buying these drugs need to be cognizant of the danger of rapid weight regain when the therapy concludes," stated lead investigator Dr. Susan Jebb.

This pace of recovery suggests a reversion to starting mass within about 18 months.

Analyzing Therapies

The study, which examined dozens of studies involving thousands of participants, contrasted the results of these new drugs with older methods.

Researchers point out that people who lose weight through diet and exercise generally see a more gradual weight regain—approximately 0.1 kg a month—after stopping.

The Reason for the Rapid Regain

Experts propose the way of the drugs is key to understanding the amplified regain.

GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate feelings of fullness.

"Long-term administration of the hormone levels several times higher than normal could lead to the body to generate a reduced amount of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics researcher.

"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making overeating a significant risk."

A Lifelong Issue?

Medical guidelines recommend the jabs for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.

A number of clinicians argue that, due to the significant potential of relapse, the treatment should be considered ongoing.

This view is reinforced by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.

Patient Experiences

Users who have stopped the medication explain a intense return of appetite.

"It felt as if something that goes on and you become extremely hungry," said an individual.

This challenge is exacerbated if users have not developed permanent dietary or behavioural modifications during therapy.

Widespread Use

Survey data indicate that a significant number of adults in the UK have used these injections in the last 12 months, with demand remaining high.

• Use is higher among women than males.
• The 40s and 50s age group shows the greatest usage rates.
• Many obtain the medications through private healthcare rather than the NHS.

In conclusion, researchers emphasize that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent fix and lasting health benefits relies on ongoing behavioural support.